Karo Pharma acquires Pevaryl[®] brand portfolio from Cilag GmbH International, an affiliate of Johnson & Johnson
Karo Pharma Aktiebolag (“Karo Pharma”) today announces the signing and closing of the acquisition of the remaining European rights to the Pevaryl[®] brand portfolio from Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for 58 MEUR. The transaction consolidates the ownership of the Pevaryl[®] brand portfolio, comprised of Pevaryl[®], Epi-Pevaryl[®], Gyno-Pevaryl[®] and Pevisone[®] in Europe with Karo Pharma. The acquired portfolio generated net sales of around 20 MEUR in 2019. Karo Pharma already owns and commercializes Pevaryl[®], Gyno-